X Square Capital LLC Grows Position in Hims & Hers Health, Inc. (NYSE:HIMS)

X Square Capital LLC lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,233 shares of the company’s stock after purchasing an additional 2,167 shares during the quarter. X Square Capital LLC’s holdings in Hims & Hers Health were worth $1,867,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Victory Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 164.9% during the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock worth $950,000 after acquiring an additional 32,108 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. Intech Investment Management LLC bought a new stake in Hims & Hers Health in the 3rd quarter worth approximately $1,064,000. Charles Schwab Investment Management Inc. boosted its stake in Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares in the last quarter. Finally, Bridgewater Associates LP grew its position in Hims & Hers Health by 63.8% during the third quarter. Bridgewater Associates LP now owns 301,072 shares of the company’s stock valued at $5,546,000 after acquiring an additional 117,251 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at $4,659,976.07. The trade was a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,061,718 shares of company stock worth $37,894,395 in the last ninety days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $31.96 on Friday. The business has a fifty day moving average price of $39.85 and a 200 day moving average price of $29.27. The company has a market cap of $7.10 billion, a P/E ratio of 72.63 and a beta of 1.37. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HIMS shares. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Bank of America increased their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Citigroup reaffirmed a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a research report on Thursday, March 6th. Finally, Truist Financial lifted their price target on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.